Gut Microbiota Altered in Mild Cognitive Impairment Compared With Normal Cognition in Sporadic Parkinson's DiseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether fecal gut microbiota composition differs between patients with Parkinson's disease (PD) who have mild cognitive impairment (PD-MCI) and those with normal cognition (PD-NC), as well as healthy controls (HC). Researchers analyzed fecal bacterial composition using 16S ribosomal RNA sequencing alongside short-chain fatty acid levels measured by gas chromatography-mass spectrometry. The study also investigated whether specific microbiota alterations were associated with cognitive ability in PD patients.
Who was studied?
The study included 13 patients with PD-MCI, 14 patients with PD-NC, and 13 healthy spouses serving as controls. Using spouses as the healthy control group suggests an effort to account for shared household and dietary environment. Statistical adjustments were made for age, sex, body mass index, education, and constipation to isolate microbiota differences related to cognitive status.
What were the most important findings?
Fecal microbial diversity was higher in both the PD-MCI and PD-NC groups compared with healthy controls. After adjusting for confounders, the PD-MCI group showed higher relative abundances of the families Rikenellaceae and Ruminococcaceae and the genera Alistipes, Barnesiella, Butyricimonas, and Odoribacter compared with the other two groups. The abundance of the genera Blautia and Ruminococcus decreased in association with cognitive impairment, indicating a distinct microbial signature linked to PD-MCI.
What are the greatest implications of this study?
These findings suggest that gut microbiota alterations may be linked specifically to cognitive impairment in Parkinson's disease, not just to PD status itself. Identifying distinct bacterial taxa associated with PD-MCI raises the possibility that fecal microbiota could serve as a biomarker for cognitive decline in PD patients. This work supports further investigation into the gut-brain axis as a factor in PD-related cognitive outcomes, though the small sample size means findings require validation in larger cohorts.